Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;10(1):180-184.
doi: 10.3892/mco.2018.1771. Epub 2018 Nov 19.

Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era

Özlem Yersal  1 , Muhammed Ali Kaplan  2 , Abdurrahman Işikdoğan  2 , Nuriye Özdemir  3 , Mehmet Aliustaoğlu  4 , Sabri Barutca  1 , Halil İbrahim Erdoğdu  5 , Nezih Meydan  1
Affiliations

Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era

Özlem Yersal et al. Mol Clin Oncol. 2019 Jan.

Abstract

Nodal (N) status and molecular subtypes are well-known prognostic factors for breast cancer patients. The aim of the present study was to evaluate whether there was a prognostic role of molecular subtypes for pN3a breast cancer patients in the modern therapeutic era. The present study retrospectively evaluated a total of 521 breast cancer patients who had 10 or more metastatic lymph nodes and received adjuvant systemic therapy at the Oncology Department of four different centers in Turkey between 2000-2015. Patients were divided into four molecular subtypes by immunohistochemical staining. There were no significant differences in relapse rates according to the molecular subtypes (P=0.07). The five year disease free survival rate was 62% for the whole study population, 67% for Luminal A tumors, 53% for Luminal B tumors, 64% for human epidermal growth factor receptor 2-positive tumors and 56% for triple negative tumors. Luminal A patients had a better progression free survival when compared with Luminal B (P=0.026) and triple negative (P=0.07) patients. pT stage (P<0.001), and breast cancer subtype (P<0.001), remained significant independent factors for disease free survival. Therefore, breast cancer subtypes are still prognostic for patients with pN3 breast cancer.

Keywords: biology; breast cancer; prognosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentage of patients according to recurrence status by subtype.
Figure 2.
Figure 2.
Kaplan-Meier curves for disease free survival according to the breast cancer subtypes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al., editors. AJCC Cancer Staging Manual. 8th edition. Springer; New York, NY: 2017. - DOI
    1. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer. 1980;45:2917–2924. doi: 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M. - DOI - PubMed
    1. Walker MJ, Osborne MD, Young DC, Schneebaum S, La Valle GJ, Farrar WB. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995;169:575–579. doi: 10.1016/S0002-9610(99)80224-4. - DOI - PubMed
    1. Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992;69:448–452. doi: 10.1002/1097-0142(19920115)69:2<448::AID-CNCR2820690229>3.0.CO;2-K. - DOI - PubMed
    1. Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M. German Breast Cancer Study Group: Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001;37:1123–1131. doi: 10.1016/S0959-8049(01)00090-9. - DOI - PubMed